Hybrid-capture sequencing platform enhances ctDNA minimal residual disease detection

◇ RESEARCH

A novel hybrid capture-based sequencing workflow combined with genome-wide features including copy number alterations, fragmentomics, and end-motif signatures was validated using reference standards, plasma samples of cancer patients, and healthy donors for tumor-informed and tumor-naïve liquid biopsy profiling. (Journal of Liquid Biopsy)